Metformina Aurovitas (Metformin Hydrochloride)

Metformin works by inhibiting hepatic glucose production and enhancing peripheral insulin sensitivity. It activates the enzyme AMP‑activated protein kinase (AMPK), which reduces gluconeogenesis in the liver and increases glucose uptake in muscle and fat tissue, thereby lowering circulating blood glucose without stimulating insulin release.

The dosage of Metformina Aurovitas is individualized by the prescribing clinician based on the patient’s renal function, glycaemic targets, and overall health status. The prescriber determines the appropriate strength, frequency, and titration schedule to achieve optimal blood‑glucose control.

The safety of metformin during pregnancy and lactation is not fully established, and the product’s pregnancy category is listed as unknown. Healthcare providers should weigh potential benefits against risks and consider alternative therapies when treating pregnant or nursing individuals.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Metformina Aurovitas belongs to the biguanide class, which differs from sulfonylureas, DPP‑4 inhibitors, or SGLT2 inhibitors. Unlike insulin‑secretagogues, metformin does not cause hypoglycaemia when used alone and primarily improves insulin sensitivity, making it a first‑line option for many patients with type 2 diabetes.

Metformina Aurovitas should be stored at room temperature, below 25 °C, in its original packaging to protect it from moisture and light. Keep the product out of reach of children and avoid storing it in humid or excessively hot environments.

Metformina Aurovitas is taken orally, usually with meals to reduce gastrointestinal discomfort. Tablets are swallowed whole with a glass of water. The exact timing and frequency are determined by the prescribing clinician based on individual therapeutic goals.

The most serious adverse effect is lactic acidosis, a rare but potentially fatal condition characterized by rapid breathing, muscle pain, and abdominal discomfort. Prompt medical attention is required if these symptoms occur, especially in patients with renal impairment or other risk factors.

Metformina Aurovitas is contraindicated in patients with severe renal impairment (eGFR < 30 mL/min/1.73 m²), known hypersensitivity to metformin, acute or chronic metabolic acidosis, and those receiving iodinated contrast agents for imaging studies. Clinicians should assess each patient’s medical history before prescribing.